Peptide reference · Library entry
Liraglutide
Saxenda
Approved product
Status as of
Metabolism
Reading note
Sketch the observation window before judging a reported change. Mark where measurement starts, when it is repeated and where the report stops following the question. In a hypothetical comparison, similar endpoints could conceal very different paths between those observations. Conversely, a difference at one visit might not describe what happened during the rest of the interval. Ask how the measurement schedule supports the wording of the claim. Keeping the timeline visible makes it easier to recognize when a conclusion extends beyond the period actually described.
Approval scope
Saxenda: weight management for eligible patients.
Mechanism
Activates the GLP-1 receptor.
Evidence
Randomized trials.
Limitations
Check other products separately.
Safety context
The label warns about severe gastrointestinal reactions.
Formulation and route
Subcutaneous injection.
Questions to take to the evidence
- When does observation begin, and what happens before that starting point?
- Which scheduled measurements support the claim about change over time?
- Does the conclusion extend beyond the final observation described in the report?
Sources
- SAXENDA
NLM · Checked
Connect the next question
Educational reference. AI-assisted editorial content; no independent human medical review. This library does not provide prescribing or self-treatment instructions.